StreetInsider.com News Articles

Form SCHEDULE 13G/A PolyPid Ltd. Filed by: Centaurus Investments Ltd

Thu, 13 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260813/26921710.html

Form SCHEDULE 13G/A PolyPid Ltd. Filed by: Centaurus Investments Ltd

Thu, 13 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260813/26921710.html

Form 6-K PolyPid Ltd. For: Jun 30

Wed, 12 Aug 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260812/26913968.html

Form 6-K PolyPid Ltd. For: Jun 30

Wed, 12 Aug 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260812/26913968.html

Form S-8 PolyPid Ltd.

Wed, 12 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260812/26912592.html

Form S-8 PolyPid Ltd.

Wed, 12 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260812/26912592.html

Form SCHEDULE 13G/A PolyPid Ltd. Filed by: Rosalind Advisors, Inc.

Wed, 12 Aug 2026 14:00:00 -0400

si-local-file:///var/storage/secattach/20260812/26911871.html

Form SCHEDULE 13G/A PolyPid Ltd. Filed by: Rosalind Advisors, Inc.

Wed, 12 Aug 2026 14:00:00 -0400

si-local-file:///var/storage/secattach/20260812/26911871.html

PolyPid Ltd. (PYPD) Tops Q2 EPS by 5c

Wed, 12 Aug 2026 07:47:27 -0400

PolyPid Ltd. (NASDAQ: PYPD) reported Q2 EPS of ($0.35), $0.05 better than the analyst estimate of ($0.40).

For earnings history and earnings-related data on PolyPid Ltd. (PYPD) click here.

Form 6-K PolyPid Ltd. For: Aug 12

Wed, 12 Aug 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260812/26908972.html

Form 6-K PolyPid Ltd. For: Aug 12

Wed, 12 Aug 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260812/26908972.html

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 07:30:00 -0400

FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance

Exclusive U.S. and Canada Commercialization Partnership with Azurity Pharmaceuticals; $30 Million in Upfront and Near-Term Milestones Achieved Following NDA Acceptance, with Over $290 Million in Additional Milestones Plus Tiered Royalties Up to Mid-Twenties Percentages

Potential U.S. Commercial Launch of D-PLEX₁₀₀ by Azurity Targeted for Early 2027

Conference Call Scheduled for Today at 8:30 AM ET

PETACH TIKVA, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd.

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 07:30:00 -0400

FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance

Potential U.S. Commercial Launch of D-PLEX₁₀₀ by Azurity Targeted for Early 2027

Conference Call Scheduled for Today at 8:30 AM ET

PETACH TIKVA, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd.

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

Thu, 30 Jul 2026 08:00:00 -0400

PETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will report its second quarter 2026 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 12, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

Thu, 30 Jul 2026 08:00:00 -0400

To ensure you are connected prior to the

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

Thu, 30 Jul 2026 08:00:00 -0400

To ensure you are connected prior to the

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

Thu, 30 Jul 2026 08:00:00 -0400

To ensure you are connected prior to the

Form 6-K PolyPid Ltd. For: Jul 29

Wed, 29 Jul 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260729/26831234.html

Form 6-K PolyPid Ltd. For: Jul 29

Wed, 29 Jul 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260729/26831234.html

FDA accepts PolyPid's D-PLEX100 NDA with priority review

Wed, 29 Jul 2026 08:30:14 -0400

PolyPid Ltd. (NASDAQ: PYPD) announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for D-PLEX100 and granted it Priority Review for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery.

The FDA set a Prescription Drug User Fee Act target action date of November 28, 2026, approximately one quarter ahead of the company's previously communicated first quarter 2027 guidance. Priority Review shortens the FDA's target review timeline from ten months to approximately six months. The agency identified no filing review issues.

The NDA acceptance triggers a $15 million milestone payment from commercial

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

Wed, 29 Jul 2026 08:30:00 -0400

PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company’s previously communicated guidance

FDA identified no Filing review issues

Acceptance triggers $15 million milestone payment, completing $30 million in upfront and near-term milestone payments under recently announced U.S. and Canada commercialization partnership

PETACH TIKVA, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that the U.S. Food and Drug Administration ("FDA") has accepted for filing the

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

Wed, 29 Jul 2026 08:30:00 -0400

PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company’s previously communicated guidance

FDA identified no Filing review issues

Acceptance triggers $15 million milestone payment, completing $30 million in upfront and near-term milestone payments under recently announced U.S. and Canada commercialization partnership

H.C. Wainwright Reiterates Buy Rating on PolyPid Ltd. (PYPD)

Wed, 22 Jul 2026 06:53:21 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $13.00 price target on PolyPid Ltd. (NASDAQ: PYPD).

The analyst commented: "PYPD announced an exclusive licensing and collaboration agreement with Azurity Pharmaceuticals (Private) for D-PLEX100 in the U.S. and Canada. We view the agreement positively, as we have consistently viewed partnering D-PLEX100 commercialization as the optimal strategy for PYPD given the slower nature of hospital launches and the capital that would otherwise be required to build a commercial organization. PYPD will receive $15M upfront and another $15M following expected FDA acceptance of the NDA in August, with up to ~$320M in

Form 6-K PolyPid Ltd. For: Jul 21

Tue, 21 Jul 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260721/26792249.html

Form 6-K PolyPid Ltd. For: Jul 21

Tue, 21 Jul 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260721/26792249.html